Press Releases
- Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial June 1, 2009 08:30 (CEST)
- Announcement of prospectus regarding rights issue in Active Biotech AB (publ) May 18, 2009 08:30 (CEST)
- Annual General Meeting of Active Biotech AB May 8, 2009 08:30 (CEST)
- NEW DATA ILLUSTRATE NOVEL MECHANISM OF ACTION OF LAQUINIMOD, AN ORAL COMPOUND FOR THE TREATMENT OF MULTIPLE SCLEROSIS April 28, 2009 15:00 (CEST)
- Active Biotech presents S100A9 as a target for quinoline compounds April 28, 2009 08:30 (CEST)
- Active Biotech AB Interim report January-March 2009 April 23, 2009 08:30 (CEST)
- Annual Report 2008 Active Biotech AB (publ) April 6, 2009 08:32 (CEST)
- The Board of Active Biotech AB proposes that the Annual General Meeting resolve to make a guaranteed rights issue of approximately SEK 256 M April 6, 2009 08:31 (CEST)
- Notice of Annual General Meeting of Shareholders April 6, 2009 08:30 (CEST)
- ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA February 12, 2009 17:28 (CET)